Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
about
CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsCDK-mediated regulation of cell functions via c-Jun phosphorylation and AP-1 activation.First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors.microRNA machinery is an integral component of drug-induced transcription inhibition in HIV-1 infection.The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis.ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanismUse of ATP analogs to inhibit HIV-1 transcription.CDK2 regulates HIV-1 transcription by phosphorylation of CDK9 on serine 90.Synthesis of New N,N'-Bis(5-arylidene-4-oxo-4,5-dihydrothiazolin-2-yl)piperazine Derivatives Under Microwave Irradiation and Preliminary Biological Evaluation.Role of cellular iron and oxygen in the regulation of HIV-1 infection.Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors.Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast CancerTargeting low molecular weight cyclin E (LMW-E) in breast cancer.Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication.The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications.Treatment of bacterial meningitis: an update.Cyclin-dependent kinase inhibitors closer to market launch?Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey.Recent advances in the identification of Tat-mediated transactivation inhibitors: progressing toward a functional cure of HIV.Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.CDK2 knockdown enhances head and neck cancer cell radiosensitivity.A conformationally fixed analog of the peptide mimic Grb2-SH2 domain: synthesis and evaluation against the A431 cancer cell.Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.Reconstitution of human MCF-7 breast cancer cells with caspase-3 does not sensitize them to action of CDK inhibitors.Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents.Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
P2860
Q27670943-525F195E-0DCD-44EA-9CC2-717F29CDA5B0Q33894814-F484FA9F-ED47-4173-9776-E1F10F179BE2Q33935146-15A95FC1-EDD3-430F-AC5A-BD009BED9A6DQ33985168-96537139-F1DB-42CA-8236-B43D9B7E4416Q34195072-85393B2A-2387-4942-9F06-263D6C1CA09AQ34359688-2833A8F0-5AE6-491A-965A-284763B14F9CQ34756557-561328F9-C277-4DFE-9C22-E3132ED74063Q34954019-DE7A4E51-34AF-403B-9C49-84DCCDA0F52EQ36202709-D9A9FB53-5CF8-487A-A5A5-C548E2D52B5CQ36448119-D514C88D-E3F3-47C7-A0F3-F7DD77D8B0A2Q36482105-83E110A9-2CB9-4B2A-BF1F-10F9B1E621A6Q36839068-FC21F1A1-A751-4E77-B2E1-A48BD3E42757Q36915824-78A30557-4C26-417B-8C5D-5E79C6752B23Q36917747-92D3E489-9FDB-47EC-8EF2-F570C810F816Q37373562-29E6443C-DEF8-4908-80D9-2FE036517FFCQ37547409-5E3F5104-5C15-4D9B-AAA8-46FAC967011DQ37948079-1CF4DF4D-8C41-468E-BFFE-D310D4EC26F0Q38044024-307FC073-124E-41C6-BF26-1F9E92F57503Q38100203-9E392129-35F7-4C1B-ACA3-48EB37A893F6Q38248633-97509568-B701-4F0B-A7D5-E3C80E7064A9Q38757713-CEA4BB13-7C81-47F9-B877-6D6ADE750B07Q38850709-7BCD100B-BE1A-4C83-AAD0-E50C0EC81DC9Q39185239-2F53C35B-9C00-4A7B-B703-1947FCFD7066Q39195560-ECF1F2F9-347F-4F90-AD1B-F7E8C2BBAF3AQ39594930-EC1FC2F2-5CB0-46BA-B3F2-A4088FC013ADQ39631323-D56DF6E8-DB39-4092-A4D4-495472214922Q41885497-A9412A00-4FBB-4EF6-8686-99642F1DA05DQ42484098-FF094C18-A45E-487B-AC55-FC8FA577797E
P2860
Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
@en
Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
@nl
type
label
Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
@en
Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
@nl
prefLabel
Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
@en
Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
@nl
P2093
P2860
P1476
Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
@en
P2093
Hervé Galons
Laurent Meijer
Nassima Oumata
P2860
P304
P356
10.1517/13543770903524284
P407
P50
P577
2010-03-01T00:00:00Z